Navigation Links
Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
Date:12/6/2011

PHILADELPHIA, Dec. 6, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep System for transdermal drug delivery, today announced positive results from its clinical study of its Symphony tCGM System in patients with type 1 and type 2 diabetes.  Data from the study confirm that Symphony successfully monitors the broad range of blood glucose values seen in people with diabetes.  Echo also announced that it plans to conduct a study in critical care patients in the near term.

"This study represents another major step in our Symphony development program.  We have now shown that Symphony represents a novel approach for the tracking and trending of glucose in patients with diabetes and holds great potential to make a meaningful impact in the management of this growing disease.  Importantly, a recent, major U.S. study demonstrated that real-time, continuous glucose monitoring gives people with type 2 diabetes, in addition to those with type 1 diabetes, improved blood glucose control," said Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics.  "We are extremely pleased with the outcome of the study and look forward to the continued success of our Symphony tCGM program, including the upcoming trial in critical care patients."

Study Results

Using over 2,600 Symphony tCGM glucose readings from the twenty (20) study subjects paired with reference blood glucose measurements, CG-EGA showed that 94.4% of the readings were clinically accurate and 2.5% were benign errors with a combined A+B of 96.9%. The MARD for the study was 12.6%.  Values for blood glucose measurements ranged from 38 to 399 mg/dL. There were no adverse events reported from the Prelude skin pe
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
2. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
4. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
5. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
6. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
7. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
8. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
9. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
10. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
11. Arno Therapeutics Announces Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... As the R&D sector becomes ... the industry to deliver better products, faster. Collaborations ... companies often means turning big ideas into reality, ... collaboration with Sensidose AB and Recipharm, is one ... to market sooner. The partnership resulted in the ...
(Date:5/21/2013)... May 21, 2013  MacroGenics, Inc. today announced ... margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), ... HER2 oncoprotein," will be presented at the 2013 ... Oncology during the Developmental Therapeutics - Immunotherapy Oral ... – 4:30 PM.  The presentation will describe the ...
(Date:5/21/2013)... 2013 Bed bugs have become so widespread ... Products, many turn to chemical-based pesticides for help to completely ... environmental risks those solutions present, the company advised the public ... instead. , According to My Cleaning Products, chemical-based pesticides ... to be. It shared that the pests have already developed ...
(Date:5/21/2013)... Inflamax scientists worked closely with internationally ... the study, which will provide critical insight into ... in the study of allergy treatments, the Environmental ... models. Although both the models are well recognized ... direct comparison between the allergic responses evoked by ...
Breaking Biology Technology:The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2
... (Nasdaq: BCRX ) today announced that it ... Industry conference in New,York. A live webcast of ... 2:00 p.m. Eastern Time may be accessed at ... be archived for seven days. (Logo: ...
... 30 Cepheid (Nasdaq:,CPHD) will present at the ... Four Seasons Hotel, Boston, September 5 to 7, ... Vice President, Finance and,Chief Financial Officer, John R. ... 7. The webcast, along with accompanying presentation ...
... Sciences,Holdings, Inc. (Nasdaq: ADLS ) today announced ... at the 2007 UBS Global Life Sciences,Conference which ... York on Wednesday,September 26 at 1:30 p.m. EDT. ... webcast of the presentation will be accessible through ...
Cached Biology Technology:BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference 2BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference 3Cepheid to Present at Thomas Weisel Partners Healthcare Conference 2Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference 2
(Date:5/18/2013)... Research presented today at Digestive Disease Week (DDW) ... about the impact of coffee on autoimmune disease and ... consumption recently has been associated with reduced risk of ... more cups of java each month also correlate with ... at the Mayo Clinic, Rochester, MN, linked coffee consumption ...
(Date:5/18/2013)... An increasing number of U.S. children are ... according to research presented at Digestive Disease Week ... researchers at the Cleveland Clinic Children,s Hospital found ... exhaled breath compared to their lean counterparts. The ... that can be correlated to potential complications associated ...
(Date:5/17/2013)... insects provide the white noise of the South, but the ... the Southern air hangs heavy from the humidity and the ... than 140 species of frogs, toads and salamanders, is the ... ponds and swamps are the auditorium for their symphonic choruses, ... Monitoring Initiative, or ARMI, have front-row seats. , ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2New research identifies risks, interventions for children's GI health 2New research identifies risks, interventions for children's GI health 3Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4
... Research in Oral Biology Award will be presented to ... at the International Association for Dental Research (IADR) 87th ... 1, 2009. , Dr. McCulloch has been professor in ... He also serves as Director of,the Canadian Institutes of ...
... medulloblastoma, the most frequent malignant brain tumor in childhood, ... spread and what the chances of disease relapse are. ... at the Heidelberg University Hospital and the German Cancer ... set of tumor markers, the intensity of treatment can ...
... American Association for Cancer Research extends its sincere ... to lead the Food and Drug Administration (FDA). ... advancement of cutting-edge products and therapies that are ... Her leadership will bring new perspectives to important ...
Cached Biology News:New tumor markers determine therapy intensity 2New tumor markers determine therapy intensity 3
...
...
... robotic workstations is designed for laboratories with ... ideal automation platform for routine sample preparation ... improving throughput, process consistency and safety. ... allows you to control the robotic and ...
Mouse polyclonal antibody to TNPO2 - transportin 2 (importin 3, karyopherin beta 2b)...
Biology Products: